Valeritas Holdings, Inc.

Equities

VLRXQ

US91914N3017

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-4.76%	-96.52%

2020	Valeritas Holdings, Inc. Went Out of Business	CI
2020	First Amended Combined Joint Liquidation Plan & Disclosure Statement Approved for Valeritas Holdings, Inc.	CI

Valeritas Holdings, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2019; Reiterates its 2019 Annual Revenue Guidance

October 02, 2019 at 12:00 pm

Valeritas Holdings, Inc. provided earnings guidance for the third quarter ending September 30, 2019. For the period, the company expects to record revenue approximately $8.5 million, as U.S. revenue grew approximately 30% over the third quarter of 2018. The Company also reiterated its 2019 annual revenue guidance of $31.0 million to $33.0 million.

Latest news about Valeritas Holdings, Inc.

Valeritas Holdings, Inc. Went Out of Business	30/06/20	CI
First Amended Combined Joint Liquidation Plan & Disclosure Statement Approved for Valeritas Holdings, Inc.	08/06/20	CI
First Motion for Exclusivity Period Extension Approved For Valeritas Holdings, Inc.	03/06/20	CI
First Motion for Exclusivity Period Extension Filed by Valeritas Holdings, Inc.	21/05/20	CI
Combined Disclosure Statement and Liquidation Plan Approved for Solicitation Purpose on Interim Basis for Valeritas Holdings, Inc.	21/04/20	CI
First Amended Combined Joint Liquidation Plan & Disclosure Statement Filed by Valeritas Holdings, Inc.	15/04/20	CI
Combined Joint Liquidation Plan & Disclosure Statement Filed by Valeritas Holdings, Inc.	06/04/20	CI
Valeritas Holdings, Inc. Announces Management Changes	02/04/20	CI
Zealand Pharma A/S completed the acquisition of substantially all assets of Valeritas Holdings, Inc.	01/04/20	CI
Motion for Asset Sale Approved for Valeritas Holdings, Inc.	20/03/20	CI
Final DIP Financing Approved for Valeritas Holdings, Inc.	13/03/20	CI
Notice for Auction Cancellation Filed by Valeritas Holdings, Inc.	13/03/20	CI
Bidding Procedure Approved for Valeritas Holdings, Inc.	06/03/20	CI
Valeritas Holdings, Inc. Terminates Joseph Saldanha as Chief Business Officer, Effective from March 6, 2020	28/02/20	CI
Valeritas Holdings, Inc.(OTCPK:VLRX.Q) dropped from NASDAQ Composite Index	19/02/20	CI
The United States Bankruptcy Court for the District of Delaware Enters an Order Granting an Interim Approval to Valeritas Holdings, Inc.'s Proposed Senior Secured Priming Debtor-In-Possession Financing Facility	14/02/20	CI
Interim DIP Financing Approved for Valeritas Holdings, Inc.	14/02/20	CI
Asset Purchase Agreement Filed by Valeritas Holdings, Inc.	14/02/20	CI
Valeritas Holdings, Inc.(NasdaqCM:VLRX) dropped from S&P TMI Index	12/02/20	CI
Motion for Joint Administration Approved for Valeritas Holdings, Inc.	12/02/20	CI
Motion for Asset Sale Filed by Valeritas Holdings, Inc.	10/02/20	CI
Valeritas Holdings, Inc. Filed for Bankruptcy	09/02/20	CI
Motion for Joint Administration Filed by Valeritas Holdings, Inc.	09/02/20	CI
Zealand Pharma A/S entered into a stalking horse agreement to acquire substantially all assets of Valeritas Holdings, Inc.	08/02/20	CI
Valeritas Holdings, Inc. Announces Appointment of Melanie Hansen as Treasurer and Principal Accounting Officer, Effective January 13, 2020	10/01/20	CI

Chart Valeritas Holdings, Inc.

Duration

Period

More charts

Company Profile

Valeritas Holdings, Inc. is a United States-based medical technology company. The Company's product, V-Go Wearable Insulin Delivery device (V-Go), is a wearable, basal-bolus insulin delivery device for adult patients requiring insulin that enables patients to administer a continuous preset basal rate of insulin over 24 hours. V-Go is a small wearable and completely disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. It has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
VALERITAS HOLDINGS, INC.	-96.52%	167K
ABBOTT LABORATORIES	-4.77%	179B
MEDTRONIC PLC	+4.10%	113B
BECTON, DICKINSON AND COMPANY	-3.85%	67.88B
DEXCOM, INC.	+5.19%	52.03B
CENCORA, INC.	+5.54%	43.3B
HOYA CORPORATION	+6.13%	41.79B
METTLER-TOLEDO INTERNATIONAL, INC.	+23.81%	32.49B
TERUMO CORPORATION	+16.16%	25.65B
WEST PHARMACEUTICAL SERVICES, INC.	-5.06%	24.55B

Other Medical Equipment, Supplies & Distribution